{"id":895,"date":"2024-01-22T13:24:40","date_gmt":"2024-02-01T13:27:48","guid":{"rendered":"https:\/\/devm.kyowakirininternational.com\/?page_id=895"},"modified":"2025-04-23T12:55:38","modified_gmt":"2025-04-23T11:55:38","slug":"areas-of-focus","status":"publish","type":"page","link":"https:\/\/kyowakirininternational.com\/noba-en\/what-we-do\/areas-of-focus\/","title":{"rendered":"Areas of Focus"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Section&#8221; _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFFFF&#8221; custom_margin=&#8221;25px||-30px||false|false&#8221; global_module=&#8221;692&#8243; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;1_3,1_3,1_3&#8243; _builder_version=&#8221;4.26.1&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#e5e5e5&#8243; width=&#8221;100%&#8221; max_width=&#8221;100%&#8221; custom_margin=&#8221;-55px||||false|false&#8221; custom_margin_tablet=&#8221;&#8221; custom_margin_phone=&#8221;&#8221; custom_margin_last_edited=&#8221;on|desktop&#8221; custom_padding=&#8221;0px|0px|0px|0px|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_3&#8243; admin_label=&#8221;Column&#8221; _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;25px|||5px|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text content_tablet=&#8221; <\/p>\n<p style=%22text-align: center;%22><a href=%22https:\/\/www.kyowakirinhub.com\/%22 data-et-target-link=%22_blank%22 rel=%22noopener%22><span style=%22color: #ff6600;%22>Healthcare Professionals Hub<\/span><\/a><\/p>\n<p> &#8221; content_phone=&#8221;<\/p>\n<p style=%22text-align: center;%22><a href=%22https:\/\/www.kyowakirinhub.com\/%22 data-et-target-link=%22_blank%22 rel=%22noopener%22><span style=%22color: #ff6600;%22>Healthcare Professionals Hub<\/span><\/a><\/p>\n<p>&#8221; content_last_edited=&#8221;on|phone&#8221; admin_label=&#8221;Text&#8221; _builder_version=&#8221;4.27.2&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;|700|||||||&#8221; text_text_color=&#8221;#ea5504&#8243; text_orientation=&#8221;center&#8221; custom_margin=&#8221;||||false|false&#8221; custom_margin_tablet=&#8221;&#8221; custom_margin_phone=&#8221;||||false|false&#8221; custom_margin_last_edited=&#8221;on|phone&#8221; custom_padding=&#8221;||||false|false&#8221; link_option_url_new_window=&#8221;on&#8221; text_text_color_tablet=&#8221;&#8221; text_text_color_phone=&#8221;&#8221; text_text_color_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/www.kyowakirinhub.com\/\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #ff6600;\">Healthcare Professionals Hub<\/span><\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; admin_label=&#8221;Column&#8221; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; admin_label=&#8221;Column&#8221; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; background_color_phone=&#8221;RGBA(255,255,255,0)&#8221; background_last_edited=&#8221;on|phone&#8221; background_enable_color_phone=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.2&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;|700|||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; background_color=&#8221;#ea5504&#8243; width=&#8221;100%&#8221; module_alignment=&#8221;center&#8221; custom_margin=&#8221;||||false|false&#8221; custom_margin_tablet=&#8221;&#8221; custom_margin_phone=&#8221;||||false|false&#8221; custom_margin_last_edited=&#8221;on|desktop&#8221; custom_padding=&#8221;10px||||false|false&#8221; link_option_url=&#8221;https:\/\/kyowakirininternational.com\/global-reporting\/&#8221; link_option_url_new_window=&#8221;on&#8221; border_color_all=&#8221;#FFFFFF&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p style=\"text-align: center;\">Report Adverse Event <img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/01\/Link-to-external-1.png\" width=\"26\" height=\"28\" alt=\"\" class=\"wp-image-615 alignnone size-full\" \/><\/p>\n<p style=\"text-align: center;\">[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; z_index=&#8221;500&#8243; width=&#8221;100%&#8221; max_width=&#8221;100%&#8221; min_height=&#8221;100px&#8221; height=&#8221;100px&#8221; overflow-x=&#8221;visible&#8221; overflow-y=&#8221;visible&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;|||25px|false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_menu menu_id=&#8221;37&#8243; active_link_color=&#8221;#ea5504&#8243; dropdown_menu_bg_color=&#8221;#5d6164&#8243; dropdown_menu_line_color=&#8221;#ff3300&#8243; dropdown_menu_text_color=&#8221;#000000&#8243; dropdown_menu_active_link_color=&#8221;#ff3300&#8243; mobile_menu_bg_color=&#8221;#b4c0c1&#8243; mobile_menu_text_color=&#8221;#000000&#8243; logo=&#8221;https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/01\/KyowaKirin_BrandLogo_colorv2-PhotoRoom-1-1024&#215;216.png&#8221; logo_url=&#8221;https:\/\/kyowakirininternational.com\/noba-en\/&#8221; logo_width=&#8221;100%&#8221; logo_max_width=&#8221;17%&#8221; show_search_icon=&#8221;on&#8221; search_icon_color=&#8221;#ea5504&#8243; menu_icon_color=&#8221;#ea5504&#8243; logo_max_width_tablet=&#8221;35%&#8221; logo_max_width_phone=&#8221;76%&#8221; logo_max_width_last_edited=&#8221;on|phone&#8221; show_search_icon_tablet=&#8221;on&#8221; show_search_icon_phone=&#8221;on&#8221; show_search_icon_last_edited=&#8221;on|phone&#8221; search_icon_color_tablet=&#8221;#ea5504&#8243; search_icon_color_phone=&#8221;#ea5504&#8243; search_icon_color_last_edited=&#8221;on|phone&#8221; _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; menu_font=&#8221;|600|||||||&#8221; menu_text_color=&#8221;#5d6164&#8243; menu_font_size=&#8221;17px&#8221; background_color=&#8221;RGBA(255,255,255,0)&#8221; custom_css_free_form=&#8221;.et_pb_menu__icon.et_pb_menu__search-button {||padding: 2% 2% 2% 1%;||||}&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_menu][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; width=&#8221;90%&#8221; max_width=&#8221;100%&#8221; custom_margin=&#8221;-25px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][lwp_divi_breadcrumbs font_icon=&#8221;&#x35;||divi||400&#8243; link_color=&#8221;#5d6164&#8243; separator_color=&#8221;#e95505&#8243; current_text_color=&#8221;#e95505&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; module_text_align=&#8221;left&#8221; background_color=&#8221;RGBA(255,255,255,0)&#8221; text_orientation=&#8221;left&#8221; animation_style=&#8221;fade&#8221; global_module=&#8221;1047&#8243; global_colors_info=&#8221;{}&#8221;][\/lwp_divi_breadcrumbs][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Section&#8221; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#5d6164&#8243; height=&#8221;50px&#8221; height_tablet=&#8221;100px&#8221; height_phone=&#8221;140px&#8221; height_last_edited=&#8221;on|phone&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;-40px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_menu menu_id=&#8221;40&#8243; menu_style=&#8221;centered&#8221; active_link_color=&#8221;#ea5504&#8243; dropdown_menu_line_color=&#8221;#ea5504&#8243; dropdown_menu_active_link_color=&#8221;#ea5504&#8243; mobile_menu_bg_color=&#8221;#b4c0c1&#8243; mobile_menu_text_color=&#8221;#000000&#8243; menu_icon_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; menu_text_color=&#8221;#FFFFFF&#8221; menu_font_size=&#8221;15px&#8221; background_color=&#8221;RGBA(255,255,255,0)&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_menu][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; next_background_color=&#8221;#FFFFFF&#8221; admin_label=&#8221;Section&#8221; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#e5e5e5&#8243; use_background_color_gradient=&#8221;on&#8221; background_color_gradient_stops=&#8221;#e4560b 0%|rgba(228,86,11,0.38) 100%&#8221; background_color_gradient_overlays_image=&#8221;on&#8221; background_image=&#8221;https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/03\/SSP1584-1-crop-1.jpg&#8221; bottom_divider_style=&#8221;curve2&#8243; bottom_divider_height=&#8221;48px&#8221; bottom_divider_repeat=&#8221;1x&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;1_2,1_2&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; header_font=&#8221;|700|||||||&#8221; header_text_color=&#8221;#FFFFFF&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h1 style=\"text-align: left;\">Our Areas of Focus<\/h1>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#FFFFFF&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>As a Japan-based global specialty pharmaceutical company, we are committed to delivering medicines and treatments with life-changing value for people impacted by under-diagnosed and under-served diseases.<\/p>\n<p>With experience in taking products \u2018from Pipeline to Patients\u2019, we utilise our expertise to maximise the impact of our medicines and technologies across multiple disease areas.<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_testimonial author=&#8221;Dr Nick Kronfeld&#8221; job_title=&#8221;Head of Medical Affairs&#8221; company_name=&#8221;Kyowa Kirin International (KKI)&#8221; portrait_url=&#8221;https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/04\/Dr-Nick-scaled-1.jpg&#8221; quote_icon_color=&#8221;#FFFFFF&#8221; quote_icon_background_color=&#8221;#ea5504&#8243; _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; body_text_color=&#8221;#FFFFFF&#8221; author_text_color=&#8221;#FFFFFF&#8221; position_text_color=&#8221;#FFFFFF&#8221; company_text_color=&#8221;#FFFFFF&#8221; background_enable_color=&#8221;off&#8221; use_background_color_gradient=&#8221;on&#8221; background_color_gradient_stops=&#8221;#e55000 0%|rgba(229,87,10,0.58) 100%&#8221; background_color_gradient_overlays_image=&#8221;on&#8221; animation_style=&#8221;slide&#8221; animation_delay=&#8221;200ms&#8221; border_color_all=&#8221;RGBA(255,255,255,0)&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><span data-contrast=\"none\" xml:lang=\"EN-GB\" lang=\"EN-GB\" class=\"TextRun SCXW202463207 BCX8\"><span class=\"NormalTextRun SCXW202463207 BCX8\">We are committed to finding novel and innovative solutions to treat some of the world\u2019s rarest diseases. We strive to make patients\u2019 lives better and to make them smile.<\/span><\/span><\/p>\n<p>[\/et_pb_testimonial][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; next_background_color=&#8221;#dbdbdb&#8221; admin_label=&#8221;Section&#8221; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFFFF&#8221; bottom_divider_style=&#8221;mountains2&#8243; bottom_divider_height=&#8221;29px&#8221; bottom_divider_repeat=&#8221;1x&#8221; bottom_divider_flip=&#8221;vertical&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; header_3_text_color=&#8221;#ea5504&#8243; link_option_url=&#8221;#ctcl&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3><b><span data-contrast=\"none\">Cutaneous T-cell lymphoma (CTCL)<\/span><\/b><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/h3>\n<p><span data-contrast=\"none\">Cutaneous T-cell lymphoma, or CTCL is a rare form of non-Hodgkin\u2019s lymphoma, a type of blood cancer, which occurs when the body makes too many white blood cells (specifically T-cells).<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; header_3_text_color=&#8221;#ea5504&#8243; link_option_url=&#8221;#xlh&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3><b><span data-contrast=\"none\">X-linked hypophosphataemia (XLH)<\/span><\/b><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/h3>\n<p>X-linked hypophosphataemia, or XLH, is a rare, inherited musculoskeletal disorder caused by a lack of phosphate.\u00a0<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; header_3_text_color=&#8221;#ea5504&#8243; link_option_url=&#8221;#tio&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3><b><span data-contrast=\"none\">Tumour-induced osteomalacia (TIO)<\/span><\/b><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/h3>\n<p>Tumour-induced osteomalacia, or TIO, is a rare, acquired disorder of phosphate and vitamin D metabolism caused by typically small endocrine tumours.<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; header_3_text_color=&#8221;#ea5504&#8243; link_option_url=&#8221;#mld&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3><b><span data-contrast=\"none\">Metachromatic leukodystrophy (MLD)<\/span><\/b><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/h3>\n<p><span data-contrast=\"none\">Metachromatic leukodystrophy, or MLD is a rare and life-threatening inherited condition of the body\u2019s metabolic system.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Section&#8221; module_id=&#8221;ctcl&#8221; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#dbdbdb&#8221; bottom_divider_style=&#8221;mountains2&#8243; bottom_divider_color=&#8221;#b7b7b7&#8243; bottom_divider_height=&#8221;24px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; header_text_color=&#8221;#ea5504&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h1 style=\"text-align: center\"><span data-contrast=\"none\" xml:lang=\"EN-US\" lang=\"EN-US\" class=\"TextRun Highlight SCXW213523588 BCX8\"><span class=\"NormalTextRun SCXW213523588 BCX8\" data-ccp-charstyle=\"normaltextrun\" data-ccp-charstyle-defn=\"{&quot;ObjectId&quot;:&quot;1753cae2-42e9-40a5-8f51-683845a4559c|210&quot;,&quot;ClassId&quot;:1073872969,&quot;Properties&quot;:[469775450,&quot;normaltextrun&quot;,201340122,&quot;1&quot;,134233614,&quot;true&quot;,469778129,&quot;normaltextrun&quot;,335572020,&quot;1&quot;,469778324,&quot;Default Paragraph Font&quot;]}\">Cutaneous T-cell Lymphoma (CTCL)<\/span><\/span><\/h1>\n<p>[\/et_pb_text][et_pb_image src=&#8221;https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/05\/Hematology-Oncology-300&#215;200-1.png&#8221; alt=&#8221;Haemato-Oncology&#8221; title_text=&#8221;Hematology-Oncology-300&#215;200&#8243; align=&#8221;center&#8221; _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; header_4_text_color=&#8221;#ea5504&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><span data-contrast=\"none\">Cutaneous T-cell lymphoma (CTCL) is a rare form of non-Hodgkin\u2019s lymphoma, a type of blood cancer, which occurs when the body makes too many white blood cells (specifically T-cells).<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">T-cells are a part of your immune system and help with the body to fight off diseases or infections. Some T-cells perform their immune function within skin and, in the case of CTCL, cancerous T-cells build up in the skin organ and can often look like a rash or raised plaque.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">It is important to understand that CTCL is a blood cancer, even though it first affects the skin.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<h4><strong><\/strong><\/h4>\n<h4><strong>DIFFERENT TYPES OF CTCL\u00a0\u00a0<\/strong><\/h4>\n<p><span data-contrast=\"none\">There are several types of CTCL that can look different on the skin, affect different parts of the body and progress at different speeds. The most well-known types are called mycosis fungoides and S\u00e9zary syndrome.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Mycosis fungoides is generally considered to follow a slow course of disease progression. It is the most common form of CTCL, accounting for around 60% of cases.<\/span><\/p>\n<p>S\u00e9zary syndrome is a more aggressive form of CTCL, differing from mycosis fungoides due to total involvement of the skin organ (erythroderma) and the greater number of cancerous T-cells detected in the blood.<strong><\/strong><\/p>\n<p>&nbsp;<\/p>\n<h4><strong>WHAT CAUSES CTCL?<\/strong><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/h4>\n<p><span data-contrast=\"none\">Experts do not know what causes CTCL. However, scientific studies have shown that it is not contagious (meaning one cannot catch it from other people or pass it on themselves), and it is unlikely to be genetic.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<h4><strong><\/strong><\/h4>\n<h4><strong>GETTING A CTCL DIAGNOSIS<\/strong><\/h4>\n<p><span data-contrast=\"none\">The first step in CTCL diagnosis is a skin biopsy; however, diagnosis is not always straightforward, even for a specialist.<\/span><\/p>\n<p>Given the rarity of the condition and the difficulty in its identification, input from clinicians across a number of specialties (e.g. dermatology, haematology, and pathology) is often required.<\/p>\n<p>Due to skin lesions in CTCL appearing similar to those in more common conditions such as eczema and psoriasis, receiving a firm CTCL diagnosis takes on average around 3 years; for some this will be quicker and for some may take even longer.<\/p>\n<p><strong><\/strong><\/p>\n<h4><strong>LIVING WITH CTCL\u00a0<\/strong><\/h4>\n<p>Living with CTCL can affect a person\u2019s emotional wellbeing because of the impact the disease has on the way they look and feel, as well as their daily life. Learn more about life with CTCL <a href=\"https:\/\/ctclanswers.com\/\" target=\"_blank\" rel=\"noopener\">here<\/a>.<\/p>\n<p>There are several organisations for people who have CTCL or other rare cancers that are able to offer practical advice on daily living and support on ways to cope with their feelings.<\/p>\n<p>Click <a href=\"https:\/\/www.clfoundation.org\/\" target=\"_blank\" rel=\"noopener\">here<\/a> to visit the Cutaneous Lymphoma Foundation, a patient advocacy organisation that supports people living with CTCL across the globe.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Section&#8221; module_id=&#8221;xlh&#8221; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#dbdbdb&#8221; bottom_divider_style=&#8221;mountains2&#8243; bottom_divider_color=&#8221;#b7b7b7&#8243; bottom_divider_height=&#8221;26px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; header_text_color=&#8221;#ea5504&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h1 style=\"text-align: center\"><span class=\"NormalTextRun SCXW121314666 BCX8\" data-ccp-charstyle=\"normaltextrun\" data-ccp-charstyle-defn=\"{&quot;ObjectId&quot;:&quot;1753cae2-42e9-40a5-8f51-683845a4559c|210&quot;,&quot;ClassId&quot;:1073872969,&quot;Properties&quot;:[469775450,&quot;normaltextrun&quot;,201340122,&quot;1&quot;,134233614,&quot;true&quot;,469778129,&quot;normaltextrun&quot;,335572020,&quot;1&quot;,469778324,&quot;Default Paragraph Font&quot;]}\">X-linked H<\/span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW121314666 BCX8\" data-ccp-charstyle=\"normaltextrun\">ypophosphataemia<\/span><span class=\"NormalTextRun SCXW121314666 BCX8\" data-ccp-charstyle=\"normaltextrun\"> (XLH)<\/span><\/h1>\n<p>[\/et_pb_text][et_pb_image src=&#8221;https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/04\/Rare-metabolic-disorders-1.jpg&#8221; alt=&#8221;Rare Metabolic Diseases&#8221; title_text=&#8221;Chromosome X and Y&#8221; align=&#8221;center&#8221; _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_text _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; header_4_text_color=&#8221;#ea5504&#8243; custom_padding=&#8221;||0px|||&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><span data-contrast=\"none\">X-linked hypophosphataemia, or XLH, is a rare, inherited musculoskeletal disorder caused by a lack of phosphate. <\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Throughout our lives, our bodies need phosphate to grow and develop properly. Phosphate is required for healthy bones, teeth, blood and muscle, and is involved in providing our bodies with energy. Most of the phosphate from our diet ends up in our teeth and bones where, alongside calcium, it is essential for lifelong bone health.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">XLH is a lifelong condition that affects children and adults differently, with symptoms that vary from person to person. These can include pseudo fractures, osteoarthritis, joint and bone pain, and dental problems.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<h4><strong><\/strong><\/h4>\n<h4><strong><span data-contrast=\"none\" xml:lang=\"EN-US\" lang=\"EN-US\" class=\"TextRun SCXW132194013 BCX8\"><span class=\"NormalTextRun SCXW132194013 BCX8\">WHAT CAUSES XLH?<\/span><\/span>\u00a0\u00a0<\/strong><\/h4>\n<p><span data-contrast=\"none\">XLH is a genetic condition that occurs due to a mutation on an\u202fX chromosome. This mutation creates an excess of fibroblast growth factor 23 (FGF23), which causes a person\u2019s kidneys to let too much phosphate pass into their urine.\u202fThis \u2018phosphate wasting\u2019 leads to low levels of phosphorus in the blood (also known as hypophosphataemia).<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Most people with XLH inherit the X-linked mutation from a parent. However, one in three people with XLH are\u202fborn with the condition despite there being no family history. This is called &#8216;spontaneous XLH&#8217;. It\u2019s not yet understood why this happens.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<h4><strong><\/strong><\/h4>\n<h4><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\"><strong><span data-contrast=\"none\" xml:lang=\"EN-US\" lang=\"EN-US\" class=\"TextRun SCXW190616266 BCX8\"><span class=\"NormalTextRun SCXW190616266 BCX8\">DIAGNOSING XLH<\/span><\/span><\/strong>\u00a0<\/span><\/h4>\n<p><span data-contrast=\"none\">XLH is normally diagnosed at a young age, around the time we first begin to walk. Common signs are short stature, bowed legs or knock-knees, and wrists or knees that appear larger than normal. <\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Due to it being such a rare condition, XLH can be mistaken for other skeletal diseases including nutritional rickets, which is caused by not eating enough vitamin D-rich foods.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<h4><strong><\/strong><\/h4>\n<h4><strong><span data-contrast=\"none\" xml:lang=\"EN-US\" lang=\"EN-US\" class=\"TextRun SCXW66227809 BCX8\"><span class=\"NormalTextRun SCXW66227809 BCX8\">LIVING WITH XLH<\/span><\/span><\/strong><\/h4>\n<p>XLH is a lifelong disease in which the symptoms and their severity may change over time. However, there are many ways that people with XLH can live full and active lives.<\/p>\n<p>And, despite the rarity of XLH, there are many specialist healthcare professionals and support groups who can provide information, help and advice.<\/p>\n<p>Click <a href=\"https:\/\/xlhalliance.org\/\" target=\"_blank\" rel=\"noopener\">here<\/a> to visit the International XLH Alliance, an international alliance of patient groups for people affected by XLH and related disorders.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Section&#8221; module_id=&#8221;tio&#8221; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#dbdbdb&#8221; bottom_divider_style=&#8221;mountains2&#8243; bottom_divider_color=&#8221;#b7b7b7&#8243; bottom_divider_height=&#8221;41px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; header_text_color=&#8221;#ea5504&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h1 style=\"text-align: center\"><span class=\"NormalTextRun SpellingErrorV2Themed SCXW57744475 BCX8\" data-ccp-charstyle=\"normaltextrun\" data-ccp-charstyle-defn=\"{&quot;ObjectId&quot;:&quot;1753cae2-42e9-40a5-8f51-683845a4559c|210&quot;,&quot;ClassId&quot;:1073872969,&quot;Properties&quot;:[469775450,&quot;normaltextrun&quot;,201340122,&quot;1&quot;,134233614,&quot;true&quot;,469778129,&quot;normaltextrun&quot;,335572020,&quot;1&quot;,469778324,&quot;Default Paragraph Font&quot;]}\">Tumour<\/span><span class=\"NormalTextRun SCXW57744475 BCX8\" data-ccp-charstyle=\"normaltextrun\">-induced O<\/span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW57744475 BCX8\" data-ccp-charstyle=\"normaltextrun\">steomalacia<\/span><span class=\"NormalTextRun SCXW57744475 BCX8\" data-ccp-charstyle=\"normaltextrun\"> (TIO)<\/span><\/h1>\n<p>[\/et_pb_text][et_pb_image src=&#8221;https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/04\/TIO_-1.png&#8221; title_text=&#8221;TIO_&#8221; align=&#8221;center&#8221; _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_text _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; header_4_text_color=&#8221;#ea5504&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Tumour-induced osteomalacia, or TIO, is a rare, acquired disorder of phosphate and vitamin D metabolism caused by typically small endocrine tumours.<\/p>\n<p>TIO is characterised by bone pain, fatigue, muscle weakness, gait disturbance and multiple fractures, which may lead to long-term disability and prolonged morbidity.<\/p>\n<h4><strong>WHAT CAUSES TIO?<\/strong><\/h4>\n<p>In TIO, small endocrine tumours secrete fibroblast growth factor 23 (FGF23), which causes a person\u2019s kidneys to let too much phosphate pass into their urine. This \u2018phosphate wasting\u2019 leads to low levels of phosphate in the blood (also known as hypophosphataemia), which impacts bone metabolism among others.<\/p>\n<h4><strong>DIAGNOSING TIO<\/strong><\/h4>\n<p>The signs and symptoms of TIO are not specific for this condition and, consequently, &gt;95% of cases may be misdiagnosed and treated incorrectly. People with TIO can often wait several years to receive an accurate diagnosis.<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Section&#8221; module_id=&#8221;mld&#8221; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#dbdbdb&#8221; bottom_divider_style=&#8221;slant2&#8243; bottom_divider_color=&#8221;#b7b7b7&#8243; bottom_divider_height=&#8221;30px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; header_text_color=&#8221;#ea5504&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h1 style=\"text-align: center\"><span data-contrast=\"none\" xml:lang=\"EN-US\" lang=\"EN-US\" class=\"TextRun Highlight SCXW86909757 BCX8\"><span class=\"NormalTextRun SCXW86909757 BCX8\" data-ccp-charstyle=\"normaltextrun\" data-ccp-charstyle-defn=\"{&quot;ObjectId&quot;:&quot;1753cae2-42e9-40a5-8f51-683845a4559c|210&quot;,&quot;ClassId&quot;:1073872969,&quot;Properties&quot;:[469775450,&quot;normaltextrun&quot;,201340122,&quot;1&quot;,134233614,&quot;true&quot;,469778129,&quot;normaltextrun&quot;,335572020,&quot;1&quot;,469778324,&quot;Default Paragraph Font&quot;]}\">Metachromatic Leukodystrophy (MLD)<\/span><\/span><\/h1>\n<p>[\/et_pb_text][et_pb_image src=&#8221;https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/04\/Gene-therapy-1.jpg&#8221; alt=&#8221;Gene Therapy&#8221; title_text=&#8221;Genetic mutation, conceptual illustration&#8221; align=&#8221;center&#8221; _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_text _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; header_4_text_color=&#8221;#ea5504&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><span data-contrast=\"none\">Metachromatic leukodystrophy (MLD) is a rare and life-threatening inherited condition of the body\u2019s metabolic system.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><i><span data-contrast=\"none\"><\/span><\/i><\/p>\n<h4><strong>WHAT CAUSES MLD?\u00a0<\/strong><\/h4>\n<p><span data-contrast=\"none\">MLD is caused by a mutation in the ARSA gene that results in the accumulation of fats, called sulfatides, in the brain and other areas of the body, including the liver, the gallbladder and kidneys.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Over time, the nervous system is damaged, and children with MLD experience neurological problems such as motor, behavioural and cognitive regression, severe spasticity and seizures, and find it increasingly difficult to move, talk, swallow, eat and see.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><i><span data-contrast=\"none\"><\/span><\/i><\/p>\n<h4><strong>THE BURDEN OF MLD\u00a0<\/strong><\/h4>\n<p><span data-contrast=\"none\">MLD is estimated to occur in approximately one in every 100,000 live births. An estimated 50% of children with the most aggressive form of MLD die within five years of disease onset if untreated.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;RGBA(255,255,255,0)&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;RGBA(255,255,255,0)&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.26.0&#8243; _module_preset=&#8221;default&#8221; header_font=&#8221;|700|||||||&#8221; header_text_color=&#8221;#ea5504&#8243; background_color=&#8221;#FFFFFF&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h1 style=\"text-align: center;\">Sources<\/h1>\n<p>\u200b<\/p>\n<ul>\n<li>Macmillan Cancer Support. Cutaneous T-cell lymphoma (CTCL). Available at: <a href=\"https:\/\/jpn01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fwww.macmillan.org.uk%2Fcancer-information-and-support%2Flymphoma%2Fnon-hodgkin%2Ftypes%2Fcutaneous-t-cell&amp;data=05%7C02%7CChris.Howden%40kyowakirin.com%7C4f8d0ac64ffe49b05a3e08dc8621f826%7C34db9a5d91ba486ebb82d37d2ee1d84c%7C0%7C0%7C638532727790067148%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&amp;sdata=v7YiVdzosfACMDV3I0WZ5eMHrnxpVqD%2F98c7ELE4lME%3D&amp;reserved=0\" target=\"_blank\" rel=\"noopener\">https:\/\/www.macmillan.org.uk\/cancer-information-and-support\/lymphoma\/non-hodgkin\/types\/cutaneous-t-cell<\/a> Accessed July 2024.<\/li>\n<li>Lymphoma Action. 2022. Skin (cutaneous) T-cell lymphoma. Available at: <a href=\"https:\/\/jpn01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Flymphoma-action.org.uk%2Ftypes-lymphoma-skin-lymphoma%2Fskin-cutaneous-t-cell-lymphoma%23diagnosis&amp;data=05%7C02%7CChris.Howden%40kyowakirin.com%7C4f8d0ac64ffe49b05a3e08dc8621f826%7C34db9a5d91ba486ebb82d37d2ee1d84c%7C0%7C0%7C638532727790077450%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&amp;sdata=y0xGv5OvT6fdTgWDVBVjUGD%2FOry2i2IvxYUSK0YkzK4%3D&amp;reserved=0\" target=\"_blank\" rel=\"noopener\">https:\/\/lymphoma-action.org.uk\/types-lymphoma-skin-lymphoma\/skin-cutaneous-t-cell-lymphoma#diagnosis<\/a> Accessed July 2024.<\/li>\n<li>Walia, Ritika, and Yeung. \u2018An Update on Molecular Biology of Cutaneous T Cell Lymphoma.\u2019 Frontiers in oncology, vol. 9, January 2020, <a href=\"https:\/\/www.frontiersin.org\/journals\/oncology\/articles\/10.3389\/fonc.2019.01558\/full\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.3389\/fonc.2019.01558<\/a> Accessed July 2024<\/li>\n<li>Kyowa Kirin. 2020. XLHLink. Available at: <a href=\"https:\/\/jpn01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fxlhlink.eu%2Findex.html&amp;data=05%7C02%7CChris.Howden%40kyowakirin.com%7C4f8d0ac64ffe49b05a3e08dc8621f826%7C34db9a5d91ba486ebb82d37d2ee1d84c%7C0%7C0%7C638532727790082028%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&amp;sdata=OX0FRXyKTjvGSc72flEqysdREoHnzxPyiWqxFOoRvlA%3D&amp;reserved=0\" target=\"_blank\" rel=\"noopener\">https:\/\/xlhlink.eu\/index.html<\/a> Accessed July 2024.<\/li>\n<li>Dahir, Kathryn, et al. &#8216;Diagnosis and Management of Tumor-Induced Osteomalacia: Perspectives from Clinical Experience.&#8217; Journal of the Endocrine Society, vol. 5, no. 9, June 2021, <a href=\"https:\/\/jpn01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fdoi.org%2F10.1210%2Fjendso%2Fbvab099&amp;data=05%7C02%7CChris.Howden%40kyowakirin.com%7C4f8d0ac64ffe49b05a3e08dc8621f826%7C34db9a5d91ba486ebb82d37d2ee1d84c%7C0%7C0%7C638532727790087250%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&amp;sdata=jGgxfb0eot7mQGd9PUNhDugoe5iLQmAFGSko2j1r3EA%3D&amp;reserved=0\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.1210\/jendso\/bvab099<\/a>. Accessed July 2024<\/li>\n<li>Orchard Therapeutics. 2020. Neurometabolic Disorders. Available at: <a href=\"https:\/\/orchard-tx.com\/focus\/#MLD\" target=\"_blank\" rel=\"noopener\">https:\/\/orchard-tx.com\/focus\/#MLD<\/a> Accessed July 2024.<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Section&#8221; _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#5d6164&#8243; custom_margin=&#8221;||||false|false&#8221; top_divider_style=&#8221;curve&#8221; top_divider_color=&#8221;#FFFFFF&#8221; top_divider_height=&#8221;71px&#8221; top_divider_repeat=&#8221;1x&#8221; top_divider_flip=&#8221;vertical&#8221; top_divider_style_tablet=&#8221;&#8221; top_divider_style_phone=&#8221;none&#8221; top_divider_style_last_edited=&#8221;on|desktop&#8221; global_module=&#8221;3452&#8243; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; width=&#8221;70%&#8221; max_width=&#8221;100%&#8221; custom_margin=&#8221;-50px||||false|false&#8221; custom_padding=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/01\/KKI-Logo-White-PhotoRoom-1-300&#215;86.png&#8221; title_text=&#8221;KKI Logo White-PhotoRoom&#8221; align=&#8221;center&#8221; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; width=&#8221;200px&#8221; width_tablet=&#8221;15%&#8221; width_phone=&#8221;50%&#8221; width_last_edited=&#8221;on|phone&#8221; module_alignment=&#8221;center&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_2,1_6,1_6,1_6&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; width=&#8221;70%&#8221; max_width=&#8221;100%&#8221; custom_padding=&#8221;||27px|||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.24.2&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#FFFFFF&#8221; header_4_text_color=&#8221;#FFFFFF&#8221; width=&#8221;100%&#8221; max_width=&#8221;100%&#8221; custom_padding=&#8221;5px|10px|5px|10px|false|false&#8221; border_width_all=&#8221;1px&#8221; border_color_all=&#8221;#FFFFFF&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p style=\"text-align: center\"><span style=\"color: #ffffff\"><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/global-reporting\/\" title=\"Report an Adverse Event\" target=\"_blank\" style=\"color: #ffffff\" rel=\"noopener\">ADVERSE EVENTS SHOULD BE REPORTED HERE<\/a><\/span><\/p>\n<p>[\/et_pb_text][et_pb_text content_tablet=&#8221;&#8221; content_phone=&#8221;&#8221; content_last_edited=&#8221;on|phone&#8221; module_class=&#8221;my-popup2&#8243; _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;||||||||&#8221; text_text_color=&#8221;#E02B20&#8243; text_orientation=&#8221;center&#8221; custom_margin=&#8221;||||false|false&#8221; custom_margin_tablet=&#8221;&#8221; custom_margin_phone=&#8221;-50px||||false|false&#8221; custom_margin_last_edited=&#8221;on|desktop&#8221; custom_padding=&#8221;||||false|false&#8221; text_font_size_tablet=&#8221;&#8221; text_font_size_phone=&#8221;&#8221; text_font_size_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p style=\"text-align: left;\"><span style=\"color: #ffffff;\"><a href=\"https:\/\/clinicaltrials.gov\/search?term=Kyowa%20Kirin&#038;city=\" target=\"_blank\" rel=\"noopener\" title=\"Clinical Trials\" style=\"color: #ffffff;\">Click here to search for Kyowa Kirin\u2019s clinical trials<\/a><\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_6&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_font_size=&#8221;16px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><span style=\"color: #ffffff\"><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/news-resource\/#press\" style=\"color: #ffffff\">Press &amp; Media<\/a><\/span><br \/><span style=\"color: #ffffff\"><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/people-careers\/\" style=\"color: #ffffff\">Careers<\/a><\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_6&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.2&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_font_size=&#8221;16px&#8221; text_text_color_tablet=&#8221;&#8221; text_text_color_phone=&#8221;&#8221; text_text_color_last_edited=&#8221;on|desktop&#8221; global_colors_info=&#8221;{}&#8221; text_text_color__hover_enabled=&#8221;on|desktop&#8221; text_text_color__hover=&#8221;#FFFFFF&#8221;]<\/p>\n<p><span style=\"color: #ffffff;\"><a href=\"https:\/\/kyowakirininternational.com\/global-reporting\/\" target=\"_blank\" style=\"color: #ffffff;\" rel=\"noopener\">Reporting<\/a><\/span><br \/><span style=\"color: #ffffff;\"><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/who-we-are\/responsibility\" style=\"color: #ffffff;\">Responsibility<\/a><\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_6&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; width=&#8221;70%&#8221; max_width=&#8221;100%&#8221; custom_padding=&#8221;||27px|||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.2&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#FFFFFF&#8221; header_text_color=&#8221;#FFFFFF&#8221; header_4_text_color=&#8221;#FFFFFF&#8221; header_6_text_color=&#8221;#FFFFFF&#8221; width=&#8221;100%&#8221; max_width=&#8221;100%&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/who-we-are\/\">ABOUT US<\/a>\u00a0 |\u00a0 <a href=\"https:\/\/kyowakirininternational.com\/noba-en\/contact-us\/\">CONTACT US<\/a>\u00a0 |\u00a0 <a href=\"https:\/\/kyowakirininternational.com\/noba-en\/notices\/\" title=\"Notices\">NOTICES<\/a>\u00a0 |\u00a0 <a href=\"https:\/\/kyowakirininternational.com\/noba-en\/notices\/\" title=\"Terms of Use\">TERMS OF USE<\/a><\/h4>\n<h4><a href=\"https:\/\/kyowakirininternational.com\/noba-en\/notices\/\" title=\"Modern Slavery Act\">MODERN SLAVERY ACT<\/a> | <a href=\"https:\/\/kyowakirininternational.com\/noba-en\/notices\/\" title=\"Third Party Code of Conduct\">THIRD PARTY CODE OF CONDUCT<\/a><\/h4>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; width=&#8221;70%&#8221; max_width=&#8221;100%&#8221; custom_margin=&#8221;-50px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.2&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#FFFFFF&#8221; width=&#8221;100%&#8221; max_width=&#8221;100%&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><span>Copyright \u00a9 Kyowa Kirin International plc. All rights reserved. This website is developed and funded by Kyowa Kirin International plc.<\/span><\/p>\n<p>Head Office Nordics &amp; Baltics:<br \/>Kyowa Kirin AB<br \/>Torshamnsgatan 39<br \/>164 40 Kista<br \/>Sweden<br \/>Tel: + 46 (8) 50 90 74 10<\/p>\n<p>Kyowa Kirin International plc is a company registered in Scotland (company number SC198780) with registered address at Galabank Business Park, Galashiels TD1 1QH, United Kingdom.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.2&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#5d6164&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.2&#8243; _module_preset=&#8221;default&#8221; width=&#8221;70%&#8221; max_width=&#8221;100%&#8221; custom_margin=&#8221;-100px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#FFFFFF&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<p>KKI\/NORD\/KKI\/0044 April 2025<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>As a Japan-based global specialty pharmaceutical company, we are committed to delivering medicines and treatments with life-changing value for people impacted by under-diagnosed and under-served diseases.<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":888,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-895","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Under-diagnosed and under-served diseases we treat | Kyowa Kirin<\/title>\n<meta name=\"description\" content=\"Kyowa Kirin: Pioneering Treatments for Rare Diseases like CTCL, XLH, MLD &amp; More. Explore innovative solutions for under-diagnosed and under-served conditions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kyowakirininternational.com\/noba-en\/what-we-do\/areas-of-focus\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Areas of Focus\" \/>\n<meta property=\"og:description\" content=\"Kyowa Kirin: Pioneering Treatments for Rare Diseases like CTCL, XLH, MLD &amp; More. Explore innovative solutions for under-diagnosed and under-served conditions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kyowakirininternational.com\/noba-en\/what-we-do\/areas-of-focus\/\" \/>\n<meta property=\"og:site_name\" content=\"Kyowa Kirin International - NOBA\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-23T11:55:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/01\/Link-to-external-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"26\" \/>\n\t<meta property=\"og:image:height\" content=\"28\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kyowakirininternational.com\/noba-en\/what-we-do\/areas-of-focus\/\",\"url\":\"https:\/\/kyowakirininternational.com\/noba-en\/what-we-do\/areas-of-focus\/\",\"name\":\"Under-diagnosed and under-served diseases we treat | Kyowa Kirin\",\"isPartOf\":{\"@id\":\"https:\/\/kyowakirininternational.com\/noba-en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kyowakirininternational.com\/noba-en\/what-we-do\/areas-of-focus\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kyowakirininternational.com\/noba-en\/what-we-do\/areas-of-focus\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/01\/Link-to-external-1.png\",\"datePublished\":\"2024-02-01T13:27:48+00:00\",\"dateModified\":\"2025-04-23T11:55:38+00:00\",\"description\":\"Kyowa Kirin: Pioneering Treatments for Rare Diseases like CTCL, XLH, MLD & More. Explore innovative solutions for under-diagnosed and under-served conditions.\",\"breadcrumb\":{\"@id\":\"https:\/\/kyowakirininternational.com\/noba-en\/what-we-do\/areas-of-focus\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kyowakirininternational.com\/noba-en\/what-we-do\/areas-of-focus\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/kyowakirininternational.com\/noba-en\/what-we-do\/areas-of-focus\/#primaryimage\",\"url\":\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/01\/Link-to-external-1.png\",\"contentUrl\":\"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/01\/Link-to-external-1.png\",\"width\":26,\"height\":28},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kyowakirininternational.com\/noba-en\/what-we-do\/areas-of-focus\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kyowakirininternational.com\/noba-en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"What We Do\",\"item\":\"https:\/\/kyowakirininternational.com\/noba-en\/what-we-do\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Areas of Focus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kyowakirininternational.com\/noba-en\/#website\",\"url\":\"https:\/\/kyowakirininternational.com\/noba-en\/\",\"name\":\"Kyowa Kirin International - NOBA\",\"description\":\"A Specialty Pharmaceutical Company\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kyowakirininternational.com\/noba-en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Under-diagnosed and under-served diseases we treat | Kyowa Kirin","description":"Kyowa Kirin: Pioneering Treatments for Rare Diseases like CTCL, XLH, MLD & More. Explore innovative solutions for under-diagnosed and under-served conditions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kyowakirininternational.com\/noba-en\/what-we-do\/areas-of-focus\/","og_locale":"en_GB","og_type":"article","og_title":"Areas of Focus","og_description":"Kyowa Kirin: Pioneering Treatments for Rare Diseases like CTCL, XLH, MLD & More. Explore innovative solutions for under-diagnosed and under-served conditions.","og_url":"https:\/\/kyowakirininternational.com\/noba-en\/what-we-do\/areas-of-focus\/","og_site_name":"Kyowa Kirin International - NOBA","article_modified_time":"2025-04-23T11:55:38+00:00","og_image":[{"width":26,"height":28,"url":"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/01\/Link-to-external-1.png","type":"image\/png"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/kyowakirininternational.com\/noba-en\/what-we-do\/areas-of-focus\/","url":"https:\/\/kyowakirininternational.com\/noba-en\/what-we-do\/areas-of-focus\/","name":"Under-diagnosed and under-served diseases we treat | Kyowa Kirin","isPartOf":{"@id":"https:\/\/kyowakirininternational.com\/noba-en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kyowakirininternational.com\/noba-en\/what-we-do\/areas-of-focus\/#primaryimage"},"image":{"@id":"https:\/\/kyowakirininternational.com\/noba-en\/what-we-do\/areas-of-focus\/#primaryimage"},"thumbnailUrl":"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/01\/Link-to-external-1.png","datePublished":"2024-02-01T13:27:48+00:00","dateModified":"2025-04-23T11:55:38+00:00","description":"Kyowa Kirin: Pioneering Treatments for Rare Diseases like CTCL, XLH, MLD & More. Explore innovative solutions for under-diagnosed and under-served conditions.","breadcrumb":{"@id":"https:\/\/kyowakirininternational.com\/noba-en\/what-we-do\/areas-of-focus\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kyowakirininternational.com\/noba-en\/what-we-do\/areas-of-focus\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/kyowakirininternational.com\/noba-en\/what-we-do\/areas-of-focus\/#primaryimage","url":"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/01\/Link-to-external-1.png","contentUrl":"https:\/\/kyowakirininternational.com\/noba-en\/wp-content\/uploads\/sites\/14\/2024\/01\/Link-to-external-1.png","width":26,"height":28},{"@type":"BreadcrumbList","@id":"https:\/\/kyowakirininternational.com\/noba-en\/what-we-do\/areas-of-focus\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kyowakirininternational.com\/noba-en\/"},{"@type":"ListItem","position":2,"name":"What We Do","item":"https:\/\/kyowakirininternational.com\/noba-en\/what-we-do\/"},{"@type":"ListItem","position":3,"name":"Areas of Focus"}]},{"@type":"WebSite","@id":"https:\/\/kyowakirininternational.com\/noba-en\/#website","url":"https:\/\/kyowakirininternational.com\/noba-en\/","name":"Kyowa Kirin International - NOBA","description":"A Specialty Pharmaceutical Company","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kyowakirininternational.com\/noba-en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"}]}},"_links":{"self":[{"href":"https:\/\/kyowakirininternational.com\/noba-en\/wp-json\/wp\/v2\/pages\/895","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kyowakirininternational.com\/noba-en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/kyowakirininternational.com\/noba-en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/kyowakirininternational.com\/noba-en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kyowakirininternational.com\/noba-en\/wp-json\/wp\/v2\/comments?post=895"}],"version-history":[{"count":34,"href":"https:\/\/kyowakirininternational.com\/noba-en\/wp-json\/wp\/v2\/pages\/895\/revisions"}],"predecessor-version":[{"id":3542,"href":"https:\/\/kyowakirininternational.com\/noba-en\/wp-json\/wp\/v2\/pages\/895\/revisions\/3542"}],"up":[{"embeddable":true,"href":"https:\/\/kyowakirininternational.com\/noba-en\/wp-json\/wp\/v2\/pages\/888"}],"wp:attachment":[{"href":"https:\/\/kyowakirininternational.com\/noba-en\/wp-json\/wp\/v2\/media?parent=895"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}